ONE-WAYDated event · through FY2024-Q3
TDM-621: Repeat Clinical Trials in Japan, Regulatory Approval and Reimbursement Coverage
A development and regulatory program for TDM-621, an absorbable topical hemostatic material, covering repeat clinical trials in Japan following discussions with the PMDA after withdrawal of the approval application, resubmission and regulatory approval, and the start of reimbursement coverage.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2016 →Last written FY2024-Q3
Directionhelps1 helps · 0 hurts · 0 flat